liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Treatment strategies in Alzheimers disease: a review with focus on selenium supplementation
Innlandet Hospital Trust, Norway; Hedmark University of Appl Science, Norway.
Norwegian Institute Public Heatlh, Norway; Norwegian University of Life Science NMBU, Norway.
Council Nutr and Environm Med, Norway.
Innlandet Hospital Trust, Norway; Hedmark University of Appl Science, Norway.
Show others and affiliations
2016 (English)In: Biometals, ISSN 0966-0844, E-ISSN 1572-8773, Vol. 29, no 5, 827-839 p.Article in journal (Refereed) Published
Abstract [en]

Alzheimers disease (AD) is a neurodegenerative disorder presenting one of the biggest healthcare challenges in developed countries. No effective treatment exists. In recent years the main focus of AD research has been on the amyloid hypothesis, which postulates that extracellular precipitates of beta amyloid (A beta) derived from amyloid precursor protein (APP) are responsible for the cognitive impairment seen in AD. Treatment strategies have been to reduce A beta production through inhibition of enzymes responsible for its formation, or to promote resolution of existing cerebral A beta plaques. However, these approaches have failed to demonstrate significant cognitive improvements. Intracellular rather than extracellular events may be fundamental in AD pathogenesis. Selenate is a potent inhibitor of tau hyperphosphorylation, a critical step in the formation of neurofibrillary tangles. Some selenium (Se) compounds e.g. selenoprotein P also appear to protect APP against excessive copper and iron deposition. Selenoproteins show anti-inflammatory properties, and protect microtubules in the neuronal cytoskeleton. Optimal function of these selenoenzymes requires higher Se intake than what is common in Europe and also higher intake than traditionally recommended. Supplementary treatment with N-acetylcysteine increases levels of the antioxidative cofactor glutathione and can mediate adjuvant protection. The present review discusses the role of Se in AD treatment and suggests strategies for AD prevention by optimizing selenium intake, in accordance with the metal dysregulation hypothesis. This includes in particular secondary prevention by selenium supplementation to elderly with mild cognitive impairment.

Place, publisher, year, edition, pages
SPRINGER , 2016. Vol. 29, no 5, 827-839 p.
Keyword [en]
Alzheimers disease; Copper; Iron; Neuroinflammation; Transmitters; Selenium
National Category
URN: urn:nbn:se:liu:diva-132523DOI: 10.1007/s10534-016-9959-8ISI: 000385252400006PubMedID: 27530256OAI: diva2:1046419
Available from: 2016-11-14 Created: 2016-11-13 Last updated: 2016-12-02

Open Access in DiVA

fulltext(590 kB)24 downloads
File information
File name FULLTEXT01.pdfFile size 590 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Alehagen, Urban
By organisation
Division of Cardiovascular MedicineFaculty of Medicine and Health SciencesDepartment of Cardiology in Linköping
In the same journal

Search outside of DiVA

GoogleGoogle Scholar
Total: 24 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 192 hits
CiteExportLink to record
Permanent link

Direct link